AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 193 filers reported holding AIMMUNE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $1,341,621,000 | +103.7% | 38,944 | -1.2% | 0.00% | – |
| Q2 2020 | $658,475,000 | +17.8% | 39,406 | +1.6% | 0.00% | – |
| Q1 2020 | $559,150,000 | -59.0% | 38,776 | -4.8% | 0.00% | -100.0% |
| Q4 2019 | $1,362,899,000 | +55.4% | 40,720 | -2.8% | 0.00% | 0.0% |
| Q3 2019 | $877,113,000 | +2.6% | 41,887 | +2.1% | 0.00% | 0.0% |
| Q2 2019 | $854,536,000 | +56.9% | 41,044 | +68.4% | 0.00% | – |
| Q1 2019 | $544,714,000 | +9.0% | 24,372 | +16.6% | 0.00% | – |
| Q4 2018 | $499,928,000 | -12.3% | 20,900 | 0.0% | 0.00% | – |
| Q3 2018 | $570,152,000 | +1.5% | 20,900 | 0.0% | 0.00% | – |
| Q2 2018 | $562,001,000 | -21.0% | 20,900 | -6.5% | 0.00% | -100.0% |
| Q1 2018 | $711,306,000 | +111.3% | 22,347 | +151.1% | 0.00% | – |
| Q4 2017 | $336,598,000 | -95.3% | 8,900 | -96.9% | 0.00% | -100.0% |
| Q3 2017 | $7,214,460,000 | – | 291,023 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,295,712 | $47,524,000 | 3.98% |
| Samsara BioCapital, LLC | 232,571 | $3,354,000 | 1.93% |
| Eventide Asset Management | 3,851,000 | $55,531,000 | 1.80% |
| Burrage Capital Management LLC | 112,546 | $1,609,000 | 1.58% |
| Avidity Partners Management LP | 408,000 | $5,883,000 | 0.81% |
| RICE HALL JAMES & ASSOCIATES, LLC | 982,484 | $14,167,000 | 0.79% |
| Bullseye Asset Management LLC | 43,374 | $626,000 | 0.75% |
| Nantahala Capital Management | 1,005,302 | $14,496,000 | 0.54% |
| ARMISTICE CAPITAL, LLC | 600,000 | $8,652,000 | 0.54% |
| Values First Advisors, Inc. | 27,042 | $389,947 | 0.47% |